This brand name is authorized in Canada, United States
The drug BEQVEZ contains one active pharmaceutical ingredient (API):
|
1
Fidanacogene elaparvovec
UNII 413EU9081Y - FIDANACOGENE ELAPARVOVEC
|
|
Fidanacogene elaparvovec is a gene therapy designed to introduce a functional copy of the high activity Padua variant of the factor IX gene (FIX-R338L) in the transduced cells to address the monogenic root cause of haemophilia B. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| BEQVEZ Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| BEQVEZ Solution for infusion | FDA, National Drug Code (US) | MPI, US: SPL/PLR |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: CA | Health Products and Food Branch | Identifier(s): 02544156 |
| Country: US | FDA, National Drug Code | Identifier(s): 0069-0422, 0069-2005, 0069-2006, 0069-2007 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
